Rhythm Pharmaceuticals, Inc. (RYTM)
After hours:
| Previous close | 51.13 |
| Open | 51.65 |
| Bid | 51.29 x 100 |
| Ask | 51.42 x 100 |
| Day's range | 51.05 - 52.08 |
| 52-week range | 20.97 - 55.64 |
| Volume | |
| Avg. volume | 444,115 |
| Market cap | 3.139B |
| Beta (5Y monthly) | 2.07 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.35 |
| Earnings date | 05 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 59.30 |
Insider MonkeyRhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish
We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) stands against the other 52-week high stocks. The start of the US Federal Reserve cutting cycle ushers a new era in the investment […]
ZacksStrength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength?
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GlobeNewswireRhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on September 11, 2024, the Compensation & Management Development Committee of Rhythm’s Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,450 shares of its common stock to four new employees. These inducement R
